Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solange Peters

Showing results (11-20 of 361) with videos related to

Pageof 37
Sort By:
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|July 29, 2015
Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancerStefan Zimmermann, Solange Peters
The New England Journal of Medicine|January 19, 2022
Targeting <i>HER2</i>-Mutant NSCLC - The Light Is OnAntonio Passaro, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2022
Minus Times Minus Equals PlusJohn Haanen, Solange Peters
Current Opinion in Oncology|January 4, 2013
Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancerSolange Peters, Etienne Meylan
Translational Lung Cancer Research|March 26, 2015
Targeted therapy in NSCLC driven by HER2 insertionsSolange Peters, Stefan Zimmermann
Cancer Treatment Reviews|April 8, 2023
Immunotherapy-based combinations in metastatic NSCLCAakash Desai, Solange Peters
Current Treatment Options in Oncology|May 30, 2018
Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor TherapySolange Peters, Stefan Zimmermann
Nature Reviews. Clinical Oncology|May 9, 2012
MET: a promising anticancer therapeutic targetSolange Peters, Alex A Adjei
The New England Journal of Medicine|November 16, 2017
Immunotherapy for Unresectable Stage III Non-Small-Cell Lung CancerNaiyer A Rizvi, Solange Peters
Nature Reviews. Clinical Oncology|December 3, 2014
Lung cancer. How much platinum-based chemotherapy is enough in NSCLC?Solange Peters, Alex A Adjei
Pageof 37

Showing results (11-20 of 361) with videos related to

Sort By:
Pageof 37
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|July 29, 2015
Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancerStefan Zimmermann, Solange Peters
The New England Journal of Medicine|January 19, 2022
Targeting <i>HER2</i>-Mutant NSCLC - The Light Is OnAntonio Passaro, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2022
Minus Times Minus Equals PlusJohn Haanen, Solange Peters
Current Opinion in Oncology|January 4, 2013
Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancerSolange Peters, Etienne Meylan
Translational Lung Cancer Research|March 26, 2015
Targeted therapy in NSCLC driven by HER2 insertionsSolange Peters, Stefan Zimmermann
Cancer Treatment Reviews|April 8, 2023
Immunotherapy-based combinations in metastatic NSCLCAakash Desai, Solange Peters
Current Treatment Options in Oncology|May 30, 2018
Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor TherapySolange Peters, Stefan Zimmermann
Nature Reviews. Clinical Oncology|May 9, 2012
MET: a promising anticancer therapeutic targetSolange Peters, Alex A Adjei
The New England Journal of Medicine|November 16, 2017
Immunotherapy for Unresectable Stage III Non-Small-Cell Lung CancerNaiyer A Rizvi, Solange Peters
Nature Reviews. Clinical Oncology|December 3, 2014
Lung cancer. How much platinum-based chemotherapy is enough in NSCLC?Solange Peters, Alex A Adjei
Pageof 37